Search results for: “keytruda”
-
Blog
A Powerful Community of Patients, Caregivers, and Advocates Gather at the Cancer Research Institute Immunotherapy Patient Summit in New York City
On Saturday, September 7, 2019, over 275 patients, survivors, caregivers, advocates, and healthcare professionals attended the CRI…
-
Blog
Curtis Garbett’s Immunotherapy Story
Bladder Cancer | Diagnosed 2015 Advancing cancer research and visioning a future immune to bladder cancer Curtis’s Story… -
Blog
FDA Approves Pembrolizumab Immunotherapy for Advanced Liver Cancer
Patients with advanced hepatocellular carcinoma (HCC), the most common form of liver cancer, can now receive PD-1…
-
Blog
First Checkpoint Immunotherapy Approved for Advanced Cervical Cancer
Pembrolizumab, a PD-1-targeting immunotherapy, was approved for recurrent advanced cervical cancer that expresses PD-L1.
-
Blog
Durvalumab Becomes First Immunotherapy Approved for Stage III Lung Cancer
Immunotherapy tripled the median progression-free survival rate among lung cancer patients compared to those who received only…
-
Blog
Recap of the Fourth Annual Immuno-Oncology 360° Conference
The Fourth Annual Immuno-Oncology 360° Conference focused on comprehensive strategies for advancing immunotherapy, and was held from February…
-
Blog
Immunotherapy is Here to Stay: Looking Back at this Year’s Breakthroughs
Important immunotherapy breakthroughs benefited patients immensely in 2017 and paved the way for even more advances in…
-
Blog
Recent FDA Announcements Herald Advances in Personalized Approaches Against Cancer
Two tumor-profiling tests recently authorized by the FDA enable doctors to tailor their treatments more effectively to…
-
Blog
Checkpoint Immunotherapy Approved for Patients with Stomach, Gastroesophageal, and Liver Cancer
Previously treated patients with these cancer types can now receive anti-PD-1 immunotherapy; nivolumab for HCC and pembrolizumab…